Quality is not just what we deliver. It is how we deliver it.

Technology alone, however, cannot create a culture of quality. Sustainable quality excellence depends on people, leadership, and shared accountability. At Piramal Pharma, quality ownership is built through a framework of Direction, Alignment, and Commitment, which creates clarity around priorities, promotes collaboration across geographies and functions, and encourages individuals at every level to take responsibility for quality outcomes. This culture is reinforced through structured capability-building programs, leadership engagement, and cross-site learning initiatives designed to strengthen technical expertise, investigation quality, regulatory awareness, and quality leadership across the organization.

This direction, alignment, and commitment is further reinforced through our Quality Meets, which bring together quality leaders across geographies to review performance, share inspection learnings, discuss emerging regulatory expectations, and align on strategic quality priorities across the network. Complementing these forums are our One Quality Townhalls, which create a common platform for communicating organizational priorities, celebrating achievements, sharing cross-site learnings, and strengthening quality culture across all levels of the organization. Together, these engagements foster transparency, collaboration, and collective ownership, ensuring that every colleague remains connected to our quality vision and committed to delivering excellence

At Piramal Pharma, every colleague is encouraged to raise concerns whenever something does not appear right from a quality, compliance, data integrity, or patient safety perspective. Supported by a structured quality escalation framework and an Open Door and Speak Up culture, employees have multiple avenues to escalate concerns, including direct access to senior quality leadership and the Chief Quality Officer. All concerns are independently reviewed, investigated as appropriate, and addressed through established governance mechanisms, ensuring transparency, objectivity, and timely resolution. This commitment to listening, acting, and learning reinforces our culture of integrity and ensures that protecting patients and product quality always remains our highest priority.

We adhere to global regulatory standards set by key authorities (including US FDA, EMA, MHRA, and PMDA). Our facilities operate under a unified Global Quality Management System (QMS) to ensure seamless compliance across all manufacturing and R&D sites worldwide.

Quality is integrated into every stage of our operations from drug discovery and manufacturing to delivery. Our approach prioritizes patient safety, operational excellence, right-first-time execution, and continuous compliance.

We operate across multiple global sites with tens of thousands of successful batches released annually, supported by regular regulatory audits, client inspections, and zero-tolerance data integrity protocols.

Leadership drives a proactive quality-first mindset through formal oversight committees, standard operating procedures, regular training programs, and transparent accountability at every level of the organization.

Yes, our QMS is harmonized globally. This ensures identical standards for risk management, batch testing, facility maintenance, and compliance, regardless of where the product is manufactured.

We maintain a state of continuous audit readiness. Through regular internal assessments, mock audits, and proactive risk evaluations, our facilities are structured to meet stringencies for unannounced and scheduled inspections.

We implement electronic QMS (eQMS), automated laboratory information management systems (LIMS), and strict ALCOA+ data integrity principles to eliminate manual errors and ensure complete traceability.

We foster a continuous improvement culture using Lean Six Sigma methodologies, root-cause analysis frameworks (CAPA), employee recognition programs, and routine quality training.

Our facilities hold active approvals and certifications from leading global regulatory agencies, including the US FDA, MHRA (UK), EMA (Europe), PMDA (Japan), ANVISA (Brazil), and Health Canada, among others.

Our promise is to deliver safe, effective, high-quality healthcare solutions built on absolute integrity, transparent partnerships, and relentless commitment to global health standards.

All suppliers, raw material vendors, and strategic partners undergo rigorous qualification, periodic audits, and raw material testing under our global vendor risk management protocol before integration into manufacturing.

Every employee undergoes continuous, role-specific GxP training, data integrity workshops, and annual compliance assessments to embed a proactive quality-first mindset at every operational level.